SCHEMBL19682805

SCHEMBL19682805

CCc1cccc(C(C)Br)c1C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 7/20 0.45
GABRB2 P47870 6/20 0.45
P2RX7 Q99572 1/20 0.37
NLRP3 Q96P20 4/20 0.36
GABRG2 P18507 2/20 0.36
GABRB3 P28472 2/20 0.36
FAAH O00519 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
LMNA P02545 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
HPGD P15428 1/20 0.35
TSHR P16473 1/20 0.35
GABRB1 P18505 1/20 0.35
PTGS1 P23219 1/20 0.35
SLC6A2 P23975 1/20 0.35
HTR2C P28335 1/20 0.35
GABRA5 P31644 1/20 0.35
GABRA3 P34903 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23845156 0.85 GABRA1 (0.45) GABRA1GABRB2NLRP3GABRG2GABRB3
SCHEMBL9621059 0.85 GABRA1 (0.44) GABRA1GABRB2NLRP3GABRG2GABRB3
SCHEMBL28105609 0.83 GABRA1 (0.33) GABRA1GABRB2
SCHEMBL27717880 0.81 GABRA1 (0.44) GABRA1GABRB2P2RX7CYP3A4TSHR
SCHEMBL11863728 0.80 P2RX7 (0.45) GABRA1GABRB2P2RX7GABRG2GABRB3
SCHEMBL20342767 0.80 CYP1A2 (0.42) GABRA1GABRB2NLRP3GABRG2GABRB3
SCHEMBL16961431 0.80 GABRA1 (0.40) GABRA1GABRB2NLRP3GABRG2GABRB3
SCHEMBL30148621 0.78 GABRA1 (0.41) GABRA1GABRB2P2RX7NLRP3GABRG2
SCHEMBL20327617 0.78 GABRA1 (0.41) GABRA1GABRB2P2RX7NLRP3GABRG2
SCHEMBL6547413 0.77 HTT (0.45) GABRA1GABRB2NLRP3GABRG2GABRB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10889555-B2 Sulfonamide compound or salt thereof TAIHO PHARMACEUTICAL CO., LTD. (JP) 2021-01-12 US disclosed
US-20200405697-A1 Antitumor Agent TAIHO PHARMACEUTICAL CO., LTD. (JP) 2020-12-31 US disclosed
US-20200399235-A1 Sulfonamide Compound or Salt Thereof TAIHO PHARMACEUTICAL CO., LTD. (JP) 2020-12-24 US disclosed
EP-3718545-A1 ANTITUMOR AGENT Taiho Pharmaceutical Co., Ltd. (JP) 2020-10-07 EP disclosed
US-20200157066-A1 Sulfonamide Compound or Salt Thereof TAIHO PHARMACEUTICAL CO., LTD. (JP) 2020-05-21 US disclosed
EP-3466934-A1 SULFONAMIDE COMPOUND OR SALT THEREOF Taiho Pharmaceutical Co., Ltd. (JP) 2019-04-10 EP disclosed
WO-2017209155-A1 SULFONAMIDE COMPOUND OR SALT THEREOF 大鵬薬品工業株式会社 2017-12-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200399235-A1 Sulfonamide Compound or Salt Thereof RNASEH1, SNRPA1, RRM2 GABRA1 4118/4885GABRB2 3825/4885P2RX7 3672/4885
US-20200157066-A1 Sulfonamide Compound or Salt Thereof RNASEH1, SNRPA1, RRM2 GABRA1 4118/4885GABRB2 3825/4885P2RX7 3672/4885
US-10889555-B2 Sulfonamide compound or salt thereof RNASEH1, SNRPA1, RRM2 GABRA1 4118/4885GABRB2 3825/4885P2RX7 3672/4885
US-20200405697-A1 Antitumor Agent HNRNPR, RRM2, RRM2B GABRA1 3641/4885GABRB2 3706/4885P2RX7 3886/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.